Sólo un registro cumplió la condición especificada en la base de información BOLMED. ()
Portada
Artículos de éste númeroArtículos de éste número
Autor: Santeliz Casavilca, Joanna V. jsanteliz@ucla.edu.ve
Oprima aquí para enviar un correo electrónico a esta dirección
Título: ARTÍCULO DE REVISIÓN: MICROBIOTA PULMONAR Y EPOC: UNA RELACIÓN CASUAL?
LUNG MICROBIOTA AND COPD: A CAUSAL RELATIONSHIP?
ISSN: 0798-0361
Fecha: 2016
Páginas/Colación: pp. 144-152
En:/ BOLETÍN MÉDICO DE POSTGRADO Vol. 32 Nro. 2 Mayo - Junio 2016
Información de existenciaInformación de existencia
Categoría Temática: Palabras: MED01 MED01
Palabras Claves del Autor: Palabras: ÉPOC ÉPOC, Palabras: MICROBIOMA MICROBIOMA, Palabras: MICROBIOTA MICROBIOTA, Palabras: PULMÓN PULMÓN
Documentos asociados
Oprima aquí para visualizar el documento PDF:Documento en formato PDF Documento en formato PDF

RESUMEN
La Enfermedad Pulmonar Obstructiva Crónica (EPOC) es una patología respiratoria con una alta morbi-mortalidad tanto en Venezuela como a nivel mundial. Esta enfermedad se caracteriza por una obstrucción progresiva, generalmente poco reversible, del flujo aéreo asociado a una disminución de la función pulmonar, comorbilidades sistémicas y en consecuencia un deterioro significativo en la calidad de vida. El factor de riesgo más importante es la exposición crónica a partículas tóxicas y gases particularmente el humo del cigarrillo. Las alteraciones anatómicas pulmonares en el paciente con EPOC son consecuencia de una respuesta inflamatoria que persiste a pesar de la cesación tabáquica. Las causas del mantenimiento de esta respuesta inflamatoria no están completamente esclarecidas. En esta revisión seactualizan conceptos relacionados con lamicrobiota pulmonar, un nuevo factor potencialmente involucrado en el desarrollo y evolución de la EPOC.
PALABRAS CLAVE: EPOC. Microbiota. Microbioma. Pulmón.

ABSTRACT
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory illness with high morbidity and mortality both in Venezuela and worldwide. This disease is characterized byprogressive, not fully reversible, airway obstruction, decrease lung function, systemic comorbidities and consequently significant deterioration in quality of life. The most important risk factor is chronic exposure to particulates and toxic gases, especially cigarette smoking. The anatomic pulmonary alterations in patients with COPD are consequence of an inflammatory response that persists despite smoking cessation. The causes responsible for the persistence of this inflammatory response are not fully clarified. In this review we update concepts about lung microbiota, a new factor potentially involved in the development and evolution of COPD
KEY WORDS: COPD. Microbiota. Microbiome. Lung.

REFERENCIAS BIBLIOGRAFICAS
1. WHO.int [Internet]. Suiza: WHO; [actualizado 20 de Julio de 2016; citado 16 de Agosto de 2016]. Disponible en: http://www.who.int/respiratory/copd/burden/en/
2. CELLI B, DECRAMER M, WEDZICHA J, WILSON K, AGUSTÍ A, CRINER G, et al. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. Am J RespirCrit Care Med 2015: 191(7): e4 - e27.
3. LEDERBERG J, MCCRAY A. OmeSweet'Omics-a genealogical treasuryof words. The Scientist 2001; 15: 8.
4. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207 - 214.
5. SIBLEY C, GRINWIS M, FIELD T, ESHAGHURSHAN C, FARÍA M, DOWD S, et al. Culture enriched molecular profiling of thecystic fibrosis airway microbiome. PLoS One 2011; 6:e22702.
6. BAUGHMAN R, THORPE J, STANECK J, RASHKIN M, FRAME P. Use of the protected specimen brush in patients with endotracheal or tracheostomy tubes. Chest 1987; 91(2): 233 - 236.
7. MIRA A. Análisis taxonómico y funcional del microbioma humano mediante aproximaciones clásicas, moleculares y metagenómicas [Tesis doctoral]. Valencia: Universidad de Valencia. Fundación para el Fomento de la Investigación Sanitaria yBiomédica de la Comunidad Valenciana (FISABIO), 2014.
8. TURNBAUGH P, LEY R, HAMADY M, FRASER-LIGGETT C, KNIGHT R, GORDON J. The human microbiome project. Nature 2007; 449: 804 - 810.
9. HAN M, HUANG Y, LIPUMA J, BOUSHEY H, BOUCHER R, COOKSON W, et al. Significance of the microbiome in obstructive lung disease. Thorax 2012; 67: 456 - 463.
10. SEGAL L, ROM W, WEIDEN M. Lung microbiome for clinicians. Ann Am ThoracSoc 2014; 11 (1): 108 - 116.
11. MORRIS A, BECK J, SCHLOSS P, CAMPBELL T, CROTHERS K, CURTIS J, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J RespirCrit Care Med 2013; 187(10): 1067 - 1075.
12. WEINREICH U, KORSGAARD J. Bacterial colonization of lower airways in health and chronic lung disease. ClinRespir J 2008; 2: 116 - 122.
13. BAGDONAS E, RAUDONIUTE J, BRUZAUSKAITE I, ALDONYTE R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J COPD 2015; 10: 995 - 1013.
14. BASSIS C, ERB-DOWNWARD J, DICKSON R, FREEMAN C, SCHMIDT T, YOUNG V, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 2015; 6(2): e00037.
15. YU G, GAIL M, CONSONNI D, CARUGNO M, HUMPHRYS M, PESATORI A, et al. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol 2016; 17: 163.
16. WARNER B, HAMVAS A. Lung, microbes and the developing neonate. Neonatology 2015; 107(4): 337 - 343.
17. SETHI S, MALONEY J, GROVE L, WRONA C, BERENSON C. Airway inflammation and bronchial bacterial colonization in chronicobstructive pulmonary disease. Am JRespirCritCareMed 2006; 173: 991 - 998. 18. WU D, HOU C, LI Y, ZHAO Z, LIU J, LUX, et al. Analysis of the bacterial community in chronic obstructive pulmonary disease sputum samples by denaturing gradient gel electrophoresis and real-time PCR. BMC Pulm Med 2014; 14: 179.
19. HILTY M, BURKE C, PEDRO H, CARDENAS P, BUSH A, BOSSLEY C, et al. Disordered microbial communitiesin asthmatic airways. PLoS One2010; 5: 1 - 9.
20. EINARSSON G, COMER D, MCLLEAVEY, PARKHILL J, ENNIS M, TUNNEY M, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonarydisease, smokers and healthy non-smokers. Thorax 2016; 71: 795 - 803.
21. SZE M, DIMITRIU P, HAYASHI S, ELLIOTT M, MCDONOUGH J, GOSSELINK J. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2012; 185(10): 1073 - 1080.
22. ANGRILL J, AGUSTI C, DE CELIS R, RANO A, GONZALEZ J, SOLE T, et al. Bacterial colonization in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15 - 19.
23. ERB-DOWNWARD J, THOMPSON D, HAN M, FREEMAN C, MCCLOSKEY L, SCHMIDT L, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011; 6(2): e16384.
24. ZAKHARKINA T, HEINZEL E, KOCZULLA R, GREULICH T, RENTZ K, PAULING J, et al. Analysis of the airway microbiota of healthy Individuals and patients with chronic obstructive pulmonary disease by T-RFLP and clone Sequencing. PLoS One 2013; 8(7): e68302.
25. CABRERA-RUBIO R, GARCÍA-NUÑEZ M, SETÓ L, ANTÓ J, MOYA A, MONSÓ E, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J ClinMicrobiol 2012; 50(11): 3562 - 3568.
26. MOLYNEAUX P, MALLIA P, COX M, FOOTITT J, WILLIS-OWEN S, HOMOLA D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2013; 188(10): 1224 - 1231.
27. PRAGMAN A, KIM H, REILLY C, WENDT C, ISAACSON R. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012; 7(10): e47305.
28. HUANG Y, KIM E, COX M, BRODIE E, BROWN R, WIENER-KRONISH J, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 2010; 14(1): 9 - 59.
29. WELTE T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009; 374: 668 - 670.
30. GARCÍA-NUÑEZ M, MILLARES L, POMARES X, FERRARI R, PÉREZ-BROCAL V, GALLEGO M. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J ClinMicrobiol 2014; 52(12): 4217 - 4223.
31. MILLARES L, FERRARI R, GALLEGO M, GARCÍA-NUÑEZ M, PÉREZ-BROCAL V, ESPASA M, et al. Bronchial microbiome of severe COPD patients colonized by Pseudomonas aeruginosa. Eur J ClinMicrobiol Infect Dis 2014; 33: 1101 - 1111.
32. CAMERON S, LEWIS K, HUWS S, LIN W, HEGARTY M, LEWIS P, et al. Metagenomic sequencing of the chronic obstructive pulmonary disease upper bronchial tract microbiome reveals functional changes associated with disease severity. PLoS One 2016; 11(2): e0149095.
33. MIRAVITLLES M, ANZUETO A. Role of infection in exacerbations of chronic obstructive pulmonary disease. CurrOpinPulm Med 2015; 21(3): 278 - 283.
34. WANG Z, BAFADHEL M, HALDAR K, SPIVAK A, MAYHEW D, MILLER B, et al. Lung microbiome dynamics in COPD exacerbations. EurRespir J 2016; 47(4): 1082 - 109.
35. STEIN M, HRUSCH C, GOZDZ J, IGARTUA C, PIVNIOUK V, MURRAY S, et al.Innate immunity and asthma risk in Amish and Hutterite farm children. NEnglJMed 2016; 375(5): 411 - 421.
36. HOOPER L, LITTMAN D, MACPHERSON A. Interactions between the microbiota and the immune system. Science 2012; 336(6086): 1268 - 1273.
37. CRAIG J, CLIFFE A, GARNETT K, HIGH N. Survival of nontypeableHaemophilusinfluenzaein macrophages. FEMS MicrobiolLett2001; 203: 55 - 61.
38. BERENSON CS, MURPHY TF, WRONA CT, SETHI S. Outer membrane protein P6 of nontypeableHaemophilus influenza is a potent and selective inducer of human macrophage proinflammatory cytokines. Infect Immun 2005; 73: 2728 - 2735.
39. MARTINEZ F, HAN M, FLAHERTY K, CURTIS J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect There 2006; 4(1): 101 - 124.
40. SETHI S, MURPHY T. Infection in the pathogenesis and courseof chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355 - 2365.
41. MATKOVIC Z, MIRAVITLLES M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med 2013; 107(1): 10 - 22.
42. TANTUCCI C, PINI L. COPD: it is time to change! Int J Chron Obstruct Pulmon Dis 2015; 10: 2451 - 2457.
43.SIMOENS S, LAEKEMAN G, DECRAMER M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med 2013; 107: 637 - 648.


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

** Back-end Alejandría BE 7.3.0b3 *